Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

ALGS

Aligos Therapeutics (ALGS)

Aligos Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALGS
DateTimeSourceHeadlineSymbolCompany
05/22/20244:05PMGlobeNewswire Inc.Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024NASDAQ:ALGSAligos Therapeutics Inc
05/22/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
05/21/20248:00AMGlobeNewswire Inc.Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASHNASDAQ:ALGSAligos Therapeutics Inc
05/15/20245:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
05/07/20244:13PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALGSAligos Therapeutics Inc
05/07/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
05/07/20244:05PMGlobeNewswire Inc.Aligos Therapeutics Reports Recent Business Progress andĀ First Quarter 2024 Financial ResultsNASDAQ:ALGSAligos Therapeutics Inc
04/30/20244:05PMGlobeNewswire Inc.Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024NASDAQ:ALGSAligos Therapeutics Inc
04/25/20244:05PMGlobeNewswire Inc.Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 StudyNASDAQ:ALGSAligos Therapeutics Inc
04/25/20248:00AMGlobeNewswire Inc.Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MDNASDAQ:ALGSAligos Therapeutics Inc
04/09/20248:00AMGlobeNewswire Inc.Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024NASDAQ:ALGSAligos Therapeutics Inc
04/03/20248:00AMGlobeNewswire Inc.Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH SubjectsNASDAQ:ALGSAligos Therapeutics Inc
03/27/20248:00AMGlobeNewswire Inc.Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 StudiesNASDAQ:ALGSAligos Therapeutics Inc
03/18/20248:00AMGlobeNewswire Inc.Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH SubjectsNASDAQ:ALGSAligos Therapeutics Inc
03/12/20244:05PMGlobeNewswire Inc.Aligos Therapeutics Reports Recent Business Progress andĀ Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALGSAligos Therapeutics Inc
03/05/20244:05PMGlobeNewswire Inc.Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024NASDAQ:ALGSAligos Therapeutics Inc
03/04/20245:44PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALGSAligos Therapeutics Inc
03/04/20245:42PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALGSAligos Therapeutics Inc
02/28/20245:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALGSAligos Therapeutics Inc
02/28/20245:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALGSAligos Therapeutics Inc
02/28/20245:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALGSAligos Therapeutics Inc
02/26/20248:00AMGlobeNewswire Inc.Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:ALGSAligos Therapeutics Inc
02/20/20248:00AMGlobeNewswire Inc.Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024NASDAQ:ALGSAligos Therapeutics Inc
02/13/20248:00AMGlobeNewswire Inc.Aligos Therapeutics Strengthens Finance Leadership Team with Two New AppointmentsNASDAQ:ALGSAligos Therapeutics Inc
01/30/20247:04AMEdgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:ALGSAligos Therapeutics Inc
01/25/20246:12AMEdgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:ALGSAligos Therapeutics Inc
01/25/20246:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
11/28/20234:01PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ALGSAligos Therapeutics Inc
11/22/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALGSAligos Therapeutics Inc
11/17/20234:38PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ALGSAligos Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ALGS